BC
NTLA icon

Bridgefront Capital’s Intellia Therapeutics NTLA Stock Holding History

Bridgefront Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238K Buy
+18,530
New +$236K 0.06% 444
2025
Q1 		– Sell
-24,521
Closed -$286K – 785
2024
Q4 		$286K Buy
24,521
+9,932
+68% +$155K 0.1% 375
2024
Q3 		$300K Buy
14,589
+5,292
+57% +$122K 0.12% 315
2024
Q2 		$208K Buy
+9,297
New +$221K 0.09% 405
2021
Q1 		– Sell
-4,334
Closed -$236K – 843
2020
Q4 		$236K Buy
+4,334
New +$157K 0.08% 460

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bridgefront Capital's NTLA Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 18,530 shares worth $238K. The stake represents 0.06% of the portfolio and ranks #444 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in NTLA as recently as Q4 2024.

Bridgefront Capital first reported a position in NTLA in Q4 2020 and has held it in 5 quarters since. The position peaked at $300K in Q3 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Bridgefront Capital held 18,530 shares of Intellia Therapeutics worth $238K as of Q1 2026.
  • Intellia Therapeutics was a new Bridgefront Capital position in Q1 2026.
  • Intellia Therapeutics made up 0.06% of Bridgefront Capital's portfolio in Q1 2026, its #444 holding.
  • Bridgefront Capital first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Bridgefront Capital's Intellia Therapeutics position peaked at $300K in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.